Update: Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT for Recurrent cSCC

Alpha Tau Medical Ltd. submitted the first module of its pre-market approval (PMA) application to the US Food and Drug Administration (FDA) as part of an application for the use of Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for surgery or standard radiation therapy, and for whom no curative systemic treatment is available.